The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) announced the recipients of the 2026 Stephenson Global Scholar Grants. In partnership...
Biogen Inc. announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing sm...
Nanjing Leads Biolabs Co., Ltd. announced that its Phase II clinical study evaluating Opamtistomig (LBL-024), a proprietary PD-L1/4-1BB bispecific antibo...
Immunologically "cold" tumors remain one of the greatest challenges in oncology, limiting the effectiveness of checkpoint inhibitors in cancers such as pla...
Targeted genetic medicines are reshaping the future of cancer treatment by improving the precision of therapeutic delivery while addressing the challenges ...
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal...
-Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin Am...
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology and c...
This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib a...
Bayer, a global life sciences company, and Henry Ford Health announced a strategic partnership to expand clinical trial opportunities for patients. The w...
In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State Univ...
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property c...
Partnership combines large-scale real-world imaging and clinical data with advanced AI capabilities to accelerate biomarker development, real-world evi...
First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targe...
© 2026 Biopharma Boardroom. All Rights Reserved.
